医学
危险系数
内科学
造血干细胞移植
化疗
累积发病率
养生
急性淋巴细胞白血病
白血病
移植
胃肠病学
化疗方案
外科
淋巴细胞白血病
置信区间
作者
Hanzhou Qi,Jun Xu,Qingxiang Yang,Ren Lin,Zhixiang Wang,Ke Zhao,Qiang Wang,Xuan Zhou,Fan Zhang,Fen Huang,Na Xu,Li Xuan,Hua Jin,Jing Sun,Robert Peter Gale,Hongsheng Zhou,Qifa Liu
标识
DOI:10.1038/s41409-022-01796-2
摘要
The optimal chemotherapy regimen pre-transplantation for adult T-cell acute lymphoblastic leukemia (T-ALL) patients remains unknown. Here, we compared the transplant outcomes in 127 subjects receiving pediatric- (N = 57) or adult-type (N = 70) regimens pre-transplant. The corresponding 3-year cumulative incidences of relapse (CIR) was 7% (95% CI: 3–11%) and 29% (95% CI: 23–35%; P = 0.02), leukemia-free survivals (LFS) was 86% (95% CI: 81–91%) and 57% (95% CI: 51–63%; P = 0.003), overall survivals (OS) was 88% (95% CI: 84–92%) and 58% (95% CI: 52–64%; P = 0.002), the 1-year NRM was 4% (95% CI: 1–7%) and 9% (95% CI: 4–14%; P = 0.40). Multivariate analysis showed that pediatric-type regimen was associated with lower CIR (Hazard Ratio [HR] = 0.31 [95% CI: 0.09–1.00]; P = 0.05), better LFS (HR = 0.34 [95% CI: 0.15–0.78]; P = 0.01) and OS (HR = 0.30 [95% CI: 0.13–0.72]; P = 0.01). Our results suggested that adult T-ALL patients undergoing allo-HSCT might benefit from pediatric-type chemotherapy.
科研通智能强力驱动
Strongly Powered by AbleSci AI